Introduction of an NT-proBNP assay to an acute admission unit--a 2-year audit.
AffiliationDivision of Internal Medicine, St. James' Hospital, Ireland.
Aged, 80 and over
Diagnostic Tests, Routine/methods/*statistics & numerical data
Inpatients/statistics & numerical data
Length of Stay/statistics & numerical data
Natriuretic Peptide, Brain/*blood
MetadataShow full item record
CitationEur J Intern Med. 2009 Jan;20(1):58-62. Epub 2008 Jul 16.
JournalEuropean journal of internal medicine
AbstractBACKGROUND: The differential diagnosis of dyspnoea is difficult due to the low predictive value of clinical and laboratory parameters. The elevated levels of NT-proBNP in congestive heart failure may improve diagnostic accuracy. We have evaluated the effect of the introduction of an NT-proBNP assay on hospital length of stay (LOS) and mortality. METHODS: There were 11,853 AMAU patient episodes in the 22 months study period (March 2005-Dec 2006). An NT-proBNP assay was requested in 657 (5.5%) of these. Comparison between categorical variables such as diagnosis, NT-proBNP testing, LOS, and in-hospital mortality was made using Chi-square tests. Literature review suggested that an NT-proBNP cut-off >or=5000 ng/L should predict acute in-patient mortality. Logistic regression analysis was used to examine the association between such an elevated NT-proBNP level and outcomes. RESULTS: Of the 396 patients with NT-proBNP <5000 ng/L, 8.1% died compared with 22.5% of the 178 patients dying with values >or=5000 ng/L (p<0.0001). An NT-proBNP >or=5000 ng/L was predictive of both LOS >or=9 days (odds ratios (OR) 1.54 (95% CI 1.06, 2.24: p=0.02) and LOS >or=14 days (OR=1.87 (95% CI 1.29, 2.71: p=0.0009). NT-proBNP requests increased over time, from 2.6% to 8.2% of all patients; the result fell in the diagnostic range for CHF in 60% of requests. CONCLUSION: The introduction of an NT-proBNP was reflected in an appropriate but rapidly increasing pattern of requests from clinicians. High NT-proBNP levels predicted in-hospital mortality and longer LOS in an acute medical population.
- Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema.
- Authors: Behnes M, Brueckmann M, Ahmad-Nejad P, Lang S, Wolpert C, Elmas E, Kaelsch T, Gruettner J, Weiss C, Borggrefe M, Neumaier M
- Issue date: 2009 Jun 26
- [Value of admission NT-proBNP in predicting in-hospital mortality in decompensated systolic heart failure].
- Authors: Wei BQ, Yang YJ, Zhang J, Zhang YH, Kang LM, Dou KF, Wang D, Lü R, Gao X, Yu LT, Wang GG, Yang YM, Tan HQ, Zhu J
- Issue date: 2009 Jul 28
- B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure.
- Authors: Gegenhuber A, Mueller T, Dieplinger B, Poelz W, Pacher R, Haltmayer M
- Issue date: 2006 Aug
- Admission NT-proBNP levels, renal insufficiency and age as predictors of mortality in elderly patients hospitalized for acute dyspnea.
- Authors: Reny JL, Millot O, Vanderecamer T, Vergnes C, Barazer I, Sedighian S, Berdagué P
- Issue date: 2009 Jan
- Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea.
- Authors: Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, Lainchbury JG, Richards AM, Ordoñez-Llanos J, Santaló M, Pinto YM, Januzzi JL Jr
- Issue date: 2007 Feb 26